# Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis

> **NCT01359813** · PHASE3 · TERMINATED · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 193 (actual)

## Conditions studied

- Cirrhosis
- Sepsis
- Renal Failure

## Interventions

- **DRUG:** Human Albumin

## Key facts

- **NCT ID:** NCT01359813
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2011-09
- **Final completion:** 2012-06
- **Target enrollment:** 193 (ACTUAL)
- **Why stopped:** decision of independent monitoring committee:Risk of death at 3 months higher in Albumin group than in control group, without reaching significance level.
- **Last updated:** 2014-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01359813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01359813, "Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01359813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*